GlaxoSmithKline plc (NYSE:GSK) – Research analysts at Jefferies Financial Group lifted their Q1 2019 EPS estimates for shares of GlaxoSmithKline in a note issued to investors on Thursday, March 14th. Jefferies Financial Group analyst P. Welford now anticipates that the pharmaceutical company will earn $0.61 per share for the quarter, up from their previous forecast of $0.60. Jefferies Financial Group has a “Buy” rating and a $45.00 price objective on the stock. Jefferies Financial Group also issued estimates for GlaxoSmithKline’s Q2 2019 earnings at $0.66 EPS, Q3 2019 earnings at $0.92 EPS, Q4 2019 earnings at $0.77 EPS, FY2019 earnings at $2.93 EPS, FY2020 earnings at $3.12 EPS, FY2021 earnings at $3.62 EPS, FY2022 earnings at $3.91 EPS and FY2023 earnings at $4.20 EPS.
GSK has been the topic of several other reports. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Wednesday, November 28th. UBS Group downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. Shore Capital downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. BNP Paribas downgraded GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. Finally, Exane BNP Paribas downgraded GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $41.99.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.09. GlaxoSmithKline had a return on equity of 160.39% and a net margin of 11.45%. The company had revenue of $10.55 billion for the quarter, compared to analyst estimates of $9.85 billion.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Friday, February 22nd will be issued a $0.597 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.39 annualized dividend and a dividend yield of 5.91%. The ex-dividend date is Thursday, February 21st. GlaxoSmithKline’s payout ratio is presently 74.68%.
Institutional investors and hedge funds have recently made changes to their positions in the company. Dubuque Bank & Trust Co. lifted its holdings in GlaxoSmithKline by 195.3% during the 4th quarter. Dubuque Bank & Trust Co. now owns 685 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 453 shares in the last quarter. Claybrook Capital LLC acquired a new position in GlaxoSmithKline during the 4th quarter worth $26,000. Berman Capital Advisors LLC acquired a new position in GlaxoSmithKline during the 4th quarter worth $32,000. 1832 Asset Management L.P. lifted its holdings in GlaxoSmithKline by 35.2% during the 4th quarter. 1832 Asset Management L.P. now owns 967 shares of the pharmaceutical company’s stock worth $37,000 after buying an additional 252 shares in the last quarter. Finally, Lavaca Capital LLC acquired a new position in GlaxoSmithKline during the 4th quarter worth $37,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.